Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Boundless Bio, Inc.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05827614CT.gov Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Skin Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bbi-825 (this asset) | Boundless Bio, Inc. | P1 | CC · 43 |
| Prednisone | Dana-Farber Cancer Institute | P4 | BB |
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer | Regeneron Pharmaceuticals | P3 | BB |
| Sirolimus | Dana-Farber Cancer Institute | P4 | BB |
| Technetium-99 | Institut de Cancérologie de Lorraine | P3 | BB |
| Indocyanine Green | Institut de Cancérologie de Lorraine | P3 | BB |
| Everolimus | Dana-Farber Cancer Institute | P4 | BB |
| Nivolumab | Fred Hutchinson Cancer Center | P2 | B |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P2 | B |
+42 more in the Skin Squamous Cell Carcinoma cohort
Other indications for Bbi-825
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Endometrial Carcinoma | — | P1 | CC · 43 |
| Head And Neck Squamous Cell Carcinoma | — | P1 | CC · 43 |
| Cervical Squamous Cell Carcinoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- PrednisoneDana-Farber Cancer InstituteBB
- Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerRegeneron PharmaceuticalsBB
- SirolimusDana-Farber Cancer InstituteBB
- Technetium-99Institut de Cancérologie de LorraineBB
- Indocyanine GreenInstitut de Cancérologie de LorraineBB
Citation
Floatz Terminal. Bbi-825 in Skin Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bbi-825-skin-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →